Current practice recommendations for grade 3 gliomas, IDH-mutant are a maximal safe surgical resection whenever feasible followed by radiotherapy (54 to 60 Gy in 1.8 to 2.0 Gy daily fractions, started 3 to 6 weeks after surgery) and chemotherapy (adjuvant PCV or adjuvant Temozolomide for oligodendroglioma, IDH-mutant and 1p/19q-codeleted, adjuvant Temozolomide for astrocytoma, IDH-mutant).6–10. The gene discussed is IDH1; the disease is glioma.